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Decay-accelerating factor (DAF), 1 which  is an inhibitor of complement and is 
present on erythrocyte membranes, was first described by Hoffmann (1,  2) and 
later isolated and characterized as an Mr 70,000  protein by Nicholson-Weller et 
al.  (3).  DAF very effectively prevents  the amplification steps of the cascade by 
interfering with assembly of the C3-convertases, C4b2a and C3bBb, and the C5- 
convertases, C4b2a3b and C3bBb3b (3-5).  The precise mechanism of action of 
DAF  is unknown  but  several lines of evidence indicate  that  it binds to  C4b or 
C3b and competitively prevents the interaction with C2 and factor B. Erythrocyte 
DAF functions only in  the  membrane  in  which  it is located,  that  is,  DAF does 
not  act  on  C3-  or  C5-convertases  formed  on  neighboring  cells  or  on  foreign 
substrates,  such  as bacteria  and  immune  complexes (5).  For  this  reason  it  has 
been suggested that the physiological role of DAF is to protect cells from damage 
by autologous complement. 
This hypothesis is in agreement with the finding that erythrocytes from patients 
with paroxysmal nocturnal  hemoglobinuria (PNH), an acquired syndrome char- 
acterized by an  unusual  susceptibility of red cells to complement activation (6), 
are DAF deficient (4,  7-9).  Platelet and leukocyte abnormalities are also found 
in PNH, but the role of DAF in these disorders is unclear (10-13). 
The idea that DAF's role is to prevent damage to autologous cells by comple- 
ment, receives further support from the findings reported here.  In the present 
study  we  used  monocional  antibodies  to  measure  the  amounts  of  DAF  on 
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peripheral blood cells from normal individuals and from patients with PNH. We 
found that  DAF  is not only present on the membrane of red cells but also on 
other  blood  elements  in  contact  with  the  complement  system,  i.e.,  platelets, 
neutrophils  (polymorphonuclear leukocytes [PMN]),  monocytes, B  and T  lym- 
phocytes.  In  PNH  patients,  we  found  DAF  deficiencies in  platelets  and  in  all 
types of leukocytes, in addition to the previously characterized red cell defect. 
Materials and Methods 
Buffers,  Antibodies,  Complement  Components, and Red Cell Hemolytic Intermediates.  We 
used as buffers Dulbecco's phosphate-buffered saline (PBS), and isotonic veronal buffer 
containing 2.47 mM sodium veronal buffer, pH 7.3, 72.7 mM NaCI, 2.5% dextrose, 0.1% 
gelatin, 0.15 mM CaCI~, and 0.5 mM  MgCI2 (DGVB++). Monoclonal anti-human CR1 
(57F) (14), rabbit anti-glycophorin A (5), guinea pig C1 (15), and human C4 and C2 (16, 
17) were prepared as described. 
Antibody-sensitized sheep erythrocytes carrying 300 hemolytic sites of guinea pig C1 
and one to two sites of human C4 (EAC 141ira) were prepared as described (5). EAC 141i,, 
cells were sensitized with DAF by incubating 5 x  10S/ml  EAC141i~ in DGVB  ÷+ with an 
equal volume of DAF (50 ng/ml) diluted in DGVB  ++ for 30 rain at 37°C.  These cells, 
termed EAC141im(DAF), were washed twice with DGVB  ÷+. As a control, EAC141im cells 
were treated in the same way with buffer alone and designated as EAC14~(buffer). 
Purification  of DAF.  DAF was purified from pooled human erythrocyte (E  hu) stroma. 
The fractionation sequence described by Nicholson-Weller et al. (3, 8) was initially used. 
E  hu ghosts from 4 U blood were extracted with butanol and the resulting butanol-saturated 
water phase was subjected to successive chromatographies using DEAE-Sephacel, phenyl- 
Sepharose (Pharmacia Fine Chemicals, Piscataway, N  J), hydroxyapatite Bio-gel HT (Bio- 
Rad  Laboratories, Richmond, CA) and lentil-lectin-Sepharose (Pharmacia Fine Chemi- 
cals).  During  purification,  DAF  was  assayed  by  its  ability  to  accelerate the  decay of 
EAC142  (3).  The  preparation  of DAF  obtained  by  this  procedure  was  treated  with 
monoclonal antibodies to CR1 (57F) coupled to Sepharose beads to remove contaminating 
CR1.  Analysis  of this preparation by sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (PAGE) (18) and silver staining (Bio-Rad Laboratories) showed the pres- 
ence of several impurities, some of which were identified as glycophorins by Western 
blotting developed with specific rabbit antibodies. 
To further purify DAF we used DEAE-Sephacel chromatography and high performance 
liquid chromatography through the TSKG 3000 SW gel filtration matrix (LKB Produkter, 
Bromma, Sweden), as follows.  The pool of impure  DAF was  dialyzed against  0.01  M 
sodium phosphate buffer, pH 8.0, containing 0.05% Nonidet P-40 (NP-40), and applied 
to a  20  ml  DEAE-Sephacel column equilibrated in  the  same buffer. The column was 
eluted with an NaCI and pH gradient formed with 50 ml of the starting buffer and 50 ml 
of 0.01  M sodium phosphate buffer, pH 6.8, containing 0.3 M NaCI and 0.05% NP-40. 
DAF eluted at 8-10 mS, slightly ahead of the main glycophorin peak. Fractions containing 
DAF and only trace amounts of glycophorin were pooled, concentrated over an Amicon 
PM30 (Amicon Corp., Lexington, MA), and applied to the TSKG 3000 SW equilibrated 
with 0.1%  NP-40  in  PBS.  Four discrete peaks  were obtained, but only the first (void 
volume) contained DAF activity and a band of  Mr 70,000, as evaluated by SDS-PAGE and 
silver staining (See Fig.  1 of reference 5). No glycophorin was detected in this preparation 
by Western blotting. 
Production  of Monoclonal Antibodies Against DAF.  BALB/c mice were immunized twice 
with 4  ~g of purified DAF in complete Freund's adjuvant.  The mice whose sera  had 
antibody titers >1:200  by Western blotting were boosted intravenously with 20 ug of 
pure DAF in 0.1% NP-40 in PBS.  After 3 d their spleen cells were fused with myeloma 
cells  (X63Ag8.653).  Culture supernatants  of the resulting hybridomas were tested for 
anti-DAF activity as described below. Three positive monoclonal antibodies, IA 10 (IgG2a), 
and IIH6 and VIIIA7 (IgG1), were obtained. 
Monoclonal antibodies were purified from culture ~pernatants with protein A-Seph- KINOSHITA ET  AL.  77 
arose (Pharmacia Fine Chemicals) by the method described by Ey et al. (19) and labeled 
with ~5I with Iodogen (Pierce Chemical Co., Rockland, IL). Larger amounts of purified 
antibodies were obtained from ascites fuids of mice bearing the hybridoma by precipita- 
tion with 50%-saturated ammonium sulfate, DEAE-Sephacel chromatography, and Seph- 
adex G-200 gel filtration. 
Detection  of Antibodies  Against  DAF  in  Hybridoma  Supernatants.  Purified  DAF  was 
subjected to SDS-PAGE under nonreducing conditions on a 7.5% gel and then transblot- 
ted onto nitrocellulose. The paper was blocked with 5% bovine serum albumin (BSA) in 
PBS containing 0.02%  sodium azide (AZ) (5%  BSA-PBS-AZ) for 1 h  at 37°C,  and cut 
into 5 ×  50 mm strips. A piece of filter paper of the same size was placed onto each strip. 
200  ~1 of hybridomas culture  supernatants  were applied  to the  filter paper.  Controls 
contained culture supernatants from unrelated monoclonals, hypoxanthine, aminopterin, 
thymidine (HAT) medium (20), and immune or normal mouse serum. After 2 h incubation 
at room temperature in a humid chamber, the filter papers were removed and the strips 
washed  individually,  three  times,  with  5  ml each  of 5%  BSA-PBS-AZ.  Groups  of  10 
washed strips were incubated  with  10  ml of 5%  BSA-PBS-AZ containing  125I-labeled, 
affinity-purified goat anti-mouse IgG (107 cpm; Cappel Laboratories, Cochranville, PA) 
at room temperature for 1 h, and washed three times with  10 ml each of 5% BSA-PBS- 
AZ.  Autoradiography was performed by exposing the  dried  strips to  Kodak X-Omat 
XAR-5 film (Eastman Kodak Co., Rochester, NY). 
Preparation of Peripheral Blood and Tonsil Cells.  Citrated blood was centrifuged at 500 
g for 10 min at 4°C. After removal of plasma and buffy coat, erythrocytes were washed 
three times with PBS. Blood samples from 35 normal individuals were obtained through 
the courtesy of Dr. Santiago Rodriguez de Cordoba (New York Blood Center). Red cells 
from three individuals were fractionated on the basis of their density by centrifugation 
into  Percoll  (Pharmacia  Fine  Chemicals)  gradient  (21).  Platelets  were  collected  from 
platelet-rich plasma by centrifugation for 10 min at 2,500 g and washed three times with 
PBS containing 10 mM EDTA. Contaminating erythrocytes and leukocytes were removed 
by centrifugation at 200 g for 10 rain. PMN and mononuclear cells were separated from 
fresh citrated blood by centrifugation on Ficoll-Paque (Pharmacia Fine Chemicals) fol- 
lowed by dextran sedimentation (22). The contaminating erythrocytes were removed by 
hypotonic lysis.  Monocytes and  lymphocytes were obtained from a  Percoll gradient as 
described by Wright and Silverstein (23). >95%  of the cells from the upper band were 
positive by indirect immunofluorescent staining with monoclonal antibody OKM5, which 
is monocyte specific.  Lymphocytes were obtained from the  lower band and  contained 
<3% contaminating monocytes (23). 
Buffy coat cells were collected from the citrated blood and washed twice with PBS by 
centrifugation at 500 g for 5 min. Contaminating erythrocytes were removed by hypotonic 
lysis. 
T  lymphocytes were obtained by staining blood mononuclear cells with phycoerythrin- 
conjugated  monoclonal  anti-Leu-1  (Becton  Dickinson  Monoclonal  Center,  Mountain 
View, CA),  followed by sorting the  Leu-1 ÷ cells in a  fluorescence-activated cell sorter 
(FACS) (Cytofluorograf 50-H; Ortho Instruments, Westwood, MA). 
Tonsil lymphocytes were purified from tonsils by centrifugation on Ficoll-Paque. T and 
B lymphocytes were isolated as described (24). 
Preparation of Cell Extracts.  Erythrocytes: 5 ×  108 packed, washed erythrocytes were 
lysed with  120  ttl  of 1%  NP-40  in  PBS  containing  50  #g/ml of the  synthetic elastase 
inhibitor, Suc (OMe)-AIa-Ala-Pro-VaI-MCA (Peninsula Laboratories, Inc., Belmont, CA) 
and  1 mM phenylmethylsulfonylfluoride (PMSF) (Sigma Chemical Co., St.  Louis, MO). 
After 1 h incubation at room temperature,  1 ml of 1% BSA in PBS containing the same 
protease inhibitors was added and the mixture centrifuged at 12,000 g for 15 min. The 
supernatant was used immediately. The concentration of erythrocytes was determined by 
measuring OD541 of the hemolysed sample. The DAF contents obtained by the two-site 
immunoradiometric assay were multiplied by 1.25 since this procedure solubilized only 
80% of extractable DAF, as determined by the following experiment. Increasing amounts 
of packed E  hu (1.5 ×  108 to 2.4 x  109) were extracted as above and the DAF contents of 78  DECAY-ACCELERATING  FACTOR  IN  NORMAL  AND  PNH  BLOOD  CELLS 
the  extracts  were  determined by two-site  immunoradiometric assay.  The amounts of 
extracted DAF per E hu were plotted as a  function of the number of E hu initially treated 
with  1%  NP-40.  We found that this amount increased slightly but progressively as the 
number of detergent-solubilized E  hu  decreased.  The  maximum amount of extractable 
DAF was obtained by extrapolation to zero E  "u (Fig. 1). 
Platelets: The platelet suspension (2 x  109/ml in PBS) was mixed with the same volume 
of 1% NP-40 in PBS containing 50 #g/ml of the elastase inhibitor, 1 mM PMSF, 5 #g/ml 
soybean trypsin inhibitor (Sigma Chemical Co.) and 100 U/ml Trasylol (Mobay Chemical 
Corp., Pittsburgh, PA). The mixture was incubated for 20 min on ice and centrifuged at 
12,000 g for 15 rain to remove the small amounts of remaining insoluble materials. 
Leukocytes: The leukocyte suspension (1  x  10S/ml in PBS) was mixed with the same 
volume of 1% NP-40 in PBS containing  the protease inhibitors. The mixture was incubated 
for 20 min on ice and centrifuged at 1,500 g for 15 min to remove intact nuclei, and the 
supernatant was centrifuged at 12,000 g for 15 min to remove insoluble materials. 
Immunoprecipitation  of DAF from  Cell  Extracts.  Protein  A-Sepharose  (100  #1)  was 
incubated with 5  ml culture supernatant of monoclonal antibody IA10 for  1 h  at room 
temperature. IA 10-Protein A-Sepharose was washed twice with PBS and then incubated 
with NP-40 extracts of different kinds of cells (20-#1 beads per  1 ml the extract) for 1 h 
at 4°C. The bound DAF molecules were eluted from the beads by incubation for 5 min 
at 80°C with 50 #1 sample buffer consisting of 5% SDS,  125 mM Tris-HCl, pH 6.8,  10% 
glycerol, 0.01% bromphenol blue. The eluates were subjected to SDS-PAGE using 7.5% 
gels and transferred electrophoretically to a  nitrocellulose paper.  DAF was detected in 
the paper by 125I-labeled IA10, IIH6, or VIIIA7, followed by autoradiography. 
In other experiments, erythrocytes, mononuclear cells, and PMN were surface labeled 
with  1251 using Iodogen (1  mCi Nal~SI  per 2  X  108 E  hu or  1  X  107  leukocytes). NP-40 
extracts were prepared and DAF was immunoprecipitated  with IA 10 or control nonrele- 
vant antibodies. The DAF band was analyzed by SDS-PAGE under reducing and nonre- 
ducing conditions, followed by autoradiography. 
Two-Site Immunoradiometric  Assay (IRMA)for DAF in Cell Extracts.  The wells of plastic 
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FIGURE  1.  Estimation of efficiency of DAF extraction from E  hu. Various amounts of washed, 
packed normal E  hu (1.5 X l0  s to 2.4 x  109) were extracted for 60 rain at room temperature 
with  120 #l of 1% Np-40 in PBS containing 1 mM PMSF and 50 ~g/ml synthetic elastase 
inhibitor. Each mixture was diluted to a concentration  of 1.5 x  108 E"U/ml  with 1% BSA-PBS 
containing the same inhibitors, and centrifuged at  12,000 g for  15 min. The supernatants 
were recovered and DAF contents measured by two-site IRMA. As shown, the efficiency of 
extraction increased as the number of solubilized E  hu decreased.  Under the conditions used 
for all the measurements (5 X 108 E  hu) included in the present paper,  we calculate that only 
80% of the total amount of DAF was extracted from the red cells. KINOSHITA ET  AL.  79 
plates (96  U-bottomed wells;  Becton,  Dickinson & Co.,  Oxnard,  CA) were coated with 
anti-DAF monoclonal IA10 (capturing antibody) by incubation with  50 ttl of 20 ttg/ml 
IA10 in PBS containing 0.02%  AZ, at room temperature  for 2 h. The wells were filled 
with  1% BSA, PBS, 0.02% AZ and kept in the cold overnight to saturate excess binding 
sites.  The wells  were  then  washed  three  times with  1%  BSA,  0.05%  Tween  20,  PBS, 
0.02%  AZ, and 25 ttl  cell extracts or serial  dilutions of pure  DAF, in  1%  BSA, 0.05% 
Tween 20, PBS, 0.02%  AZ, were added in duplicate.  After incubation for 2 h  at room 
temperature  and  three  washes  with  the  same  buffer,  25  ttl  of ~5I-labeled  anti-DAF 
monoclonal IIH6 (revealing antibody) (4 ng,  1.2  ×  105 cpm) were added to each well. 
After incubation for 1 h at room temperature, the wells were washed four time~ with the 
same buffer, cut,  and counted. The amount of DAF in the cell extracts was calculated 
from a standard curve obtained with purified DAF. This curve, in which counts bound of 
the revealing antibody were plotted as a function of DAF concentration, was linear up to 
250 ng DAF/ml. The protein concentration of the pure DAF solution was measured by 
the method of Lowry et al. (25) using BSA as a reference protein. 
FACS Analysis of Cell Surface DAF.  Erythrocytes, platelets,  or buffy coat ceils  from 
normal individuals and PNH patients were treated with anti-DAF monoclonal antibodies 
and fluorescein-conjugated goat F(ab')~ anti-mouse IgG (heavy and light chains)(Cappel 
Laboratories), and then analyzed by FACS. Erythrocytes (106 cells in 25 ttl of 1%  BSA, 
PBS,  0.1%  AZ) were  treated  with  25  ~tl  of a  mixture  of three  monoclonal antibodies 
against DAF (5/zg each per milliliter in  1% BSA, PBS, 0.1% AZ) or, as a control, with a 
mixture of nonrelevant monoclonal antibodies of the same subclass. After incubation for 
30 min on ice, the red cells were washed twice, resuspended in 25 ttl of the same buffer, 
incubated with 25 ttl  of a  1:50 dilution of the second antibody for 30 min on ice, and 
washed again with the same buffer. Buffy coat cells (106 ceils in 25 ttl of the same buffer) 
were incubated with 25 ttl of 5 ttg/ml IA10 or control monoclonal antibodies for 30 rain 
on ice. This was followed by washing and incubation with the second antibody as above. 
Platelets were stained  in the same way as the red cells, except that  10 mM  EDTA was 
added to the buffer. 
Isolation of DAF-positive and DAF-negative Erythrocytes  from PNH Patients.  DAF-positive 
erythrocytes: Washed erythrocytes from PNH patients were incubated with 60% acidified 
human serum (10 s EhU/ml) for 30 min at 37 °C (7, 26). Unlysed erythrocytes were pelleted 
and washed twice with PBS.  DAF-negative cells were selectively lysed by this procedure 
(see below). 
DAF-negative erythrocytes: Erythrocytes from PNH patients (10  s EhU/ml in PBS, 0.02% 
AZ) were mixed with an equal volume of 10/zg/ml IA 10 anti-DAF. After incubation for 
60 rain on ice, cells were washed once with PBS, 0.02%  AZ, resuspended at  109 Eh"/ml, 
and then loaded into a protein A-Sepharose CL-4B column (2 X  l0 s EhU/ml packed gel) 
equilibrated  in the same buffer.  The column was closed and kept for  15  min at room 
temperature.  Unbound  cells  were  collected  by  washing  the  column  with  five column 
volumes of the same buffer. >90% of the unbound cells were DAF-negative as assessed 
by FACS analysis. 
Patients.  Three patients with PNH at the New York University Medical Center were 
studied.  Patient GC, a  46-yr-old Hispanic female, had severe disease of 17 yr duration. 
She was receiving norandralone, prednisone, and transfusions of frozen-thawed erythro- 
cytes. Patient SB, a 47-yr-old Caucasian female, had milder disease of 4 yr duration. She 
was receiving no medication and  maintained  a  stable  hematocrit of ~38  vol %,  which, 
during episodes of hemolysis, decreased to 24%. Patient VR is a 46-yr-old Hispanic female, 
with  pancytopenia and  persistent  thrombocytopenia (platelets,  20,000/mm s) and  inter- 
mittent anemia. She is being treated with norandralone and prednisone. All patients had 
a positive acid serum (Ham) test and sucrose hemolysis test. 
Results 
Characterization  of  Anti-DAF  Monoclonal  Antibodies  IAIO,  IIH6,  and 
VIIIA7.  The  specificity  of the  anti-DAF  monocional  antibodies  was  shown  by 80  DECAY-ACCELERATING  FACTOR  IN  NORMAL  AND  PNH  BLOOD  CELLS 
Western blotting experiments using as antigen either purified DAF or the total 
extract of E hu membranes (Fig. 2). Culture supernatants of the anti-DAF hybrid- 
omas were incubated with nitrocellulose strips previously blotted with pure DAF 
(Fig. 2A).  All anti-DAF antibodies, but not HAT  medium or monoc|onal anti- 
bodies to  CR1  (57F),  detected  the  DAF  band.  When  the  nitrocellulose strips 
were  blotted  with  crude  membrane  extracts  of E hu,  the  results were  identical 
(Fig. 2B). 
IA10, IIH6, and VIIIA7 recognized different epitopes on the DAF molecule, 
since the solid phase two-site IRMA  described in Materials and Methods could 
FIGURE 2.  Detection of antibodies to DAF in culture supernatants of hybridomas by means 
of Western blotting. (A) Pure DAF was subjected to SDS-PAGE under nonreducing  conditions 
and then transblotted onto a nitrocellulose paper.  Each strip (containing 10 ng DAF) of the 
paper was incubated for 2 h at room temperature with 200 ~tl of culture supernatants from 
hybridomas IA10 (lane 1), IIH6 (2), VIIlA7 (3), and 57F anti-CR1 (5); or with HAT medium 
(4). After washing, the strips were incubated with l~Sl-labeled  goat anti-mouse IgG, washed, 
and exposed to film. Anti-DAF antibodies,  but not anti-CRl or HAT medium, detected the 
DAF band. (B)  Washed E  hu (5 x  10  s cells) were lysed with 15 mM Tris-HCl buffer, pH 7.8. 
Ghosts were collected by centrifugation, solubilized with nonreducing SDS sample buffer by 
boiling, and subjected  to SDS-PAGE on a  7.5% gel,  followed by Western  blotting. Each 
nitrocellulose  strip  (containing total  membrane proteins derived from  3  x  10  7  E  ~u)  was 
incubated with culture supernatant from hybridomas  IAI0 (lane 1), IIH6 (2), VIIIA7 (3), 
and 57F anti-CR1 (5); or with HAT medium (4). This was followed by incubation with the 
second antibody and autoradiography as described above. Anti-DAF antibodies detected one 
band with Mr 70,000. Control anti-CR1 detected two types of CRI. KINOSHITA  ET  AL.  81 
be  performed  with  any  combination  of two  different  monoclonal  antibodies, 
while negative results were obtained if a  single one was used as the  capturing 
and revealing reagent. 
The effect of monoclonal antibodies on the activity of DAF was tested using 
DAF-treated EAC141im cells (Table I). IA10, IIH6, or VIIIA7 alone had no or 
only  a  slight  effect  on  DAF  activity.  However,  when  combinations  of these 
antibodies were used, stronger effects were observed, except for the combination 
of IA 10 and VIIIA7. A mixture of three monoclonal antibodies at concentrations 
of 9/xg/ml  each inhibited 98% of DAF activity. These results suggest that  the 
binding sites of these antibodies do not coincide with the active site of the DAF 
molecule. Perhaps the inhibition of DAF activity by the combination of  antibodies 
results from aggregation of the molecule and/or steric hindrance. 
Demonstration of the Presence of DAF on Different Cell Populations by Immunopre- 
TABLE  I 
Effect of the Monoclonal Antibodies to DAF on the Inhibitory Activity 
of DAF on C4b Hemolytic Sites 
Concentration of monoclonal antibodies  Percent reversal 
IA 10  IIH6  VIIIA7  of DAF activity* 
ug/ml 
9  --  --  7.0 
--  9  --  27.5 
--  --  9  0 
1  1  --  44.6 
3  3  --  70.3 
9  9  --  78.6 
1  --  1  11.7 
3  --  3  15.7 
9  --  9  18.3 
1  1  29.9 
3  3  56.4 
9  9  72.0 
1  1  1  55.8 
3  3  3  84.5 
9  9  9  98.0 
100  #1 of  1  X  10a/ml  EAC1411,,(DAF)  in  DGVB  ++ were  incubated at 
30°C  for  15  min with  100 tal of various combinations of monoclonal 
antibodies to DAF, or DGVB  ++ as controls. EAC1411m(buffer) cells were 
treated with DGVB  ++ in the same way to measure input C4b hemolytic 
sites. After incubation,  the cells were  washed once with  DGVB  ++ and 
resuspended in DGVB  ++. Then the C4b hemolytic sites were developed 
with C2, followed by C3-9, as described (5). Degree of lysis was deter- 
mined by OD4~2 of released hemoglobin in the supernatant. 
Percent  reversal  of  DAF  activity  was  calculated  as  follows:  ([Z  of 
anti-DAF-treated  EACI4nm(DAF)  -  Z  of  EACI411m(DAF)]/[Z  of 
EAC 1411~.(buffer)  -- Z of EAC 141im(DAF)])  X 100, where Z is the number 
of hemolytic sites per cell. Z of EAC 141ira(buffer) and EAC 14~I=(DAF) in 
this experiment were 2.480 and 0.700, respectively. 82  DECAY-ACCELERATING  FACTOR  IN  NORMAL  AND  PNH  BLOOD  CELLS 
cipitation.  NP-40  extracts  of platelets,  PMN,  blood  mononuclear  cells,  tonsil 
mononuclear cells, tonsil  B  and T  lymphocyte fractions,  and a  solution  of pure 
erythrocyte DAF, were incubated with IA 10-bearing protein A-Sepharose beads. 
DAF was eluted  from the beads and subjected  to Western  blotting.  All the cell 
types contained  DAF (Fig.  3).  DAF from all cells shared at least three epitopes, 
since all bands could be detected by l~SI-labeled IIH6 or VIIIA7, as well as IA10. 
The Mr of the DAF band was different in different cell types (Fig. 3). DAF from 
platelets  and  PMN  appeared  larger (~5,000  Mr) than  DAF  from erythrocytes, 
while DAF from mononuclear cells was of intermediate size. The size difference 
was  also  shown  by  immunoprecipitation  of  DAF  from  surface-labeled  cells, 
followed by SDS-PAGE  under  both reducing  and  nonreducing  conditions  (not 
shown). 
Quantitation  of DAF  in  Different  Cell  Types from  Normal  Individuals.  DAF 
contents  were  measured  in  NP-40  extracts  of cells  using a  two-site  IRMA.  As 
shown  in  Table  II, erythrocytes from normal individuals  had  a  mean of 3.3  _+ 
0.4  x  l0 s molecules per cell,  ranging between  4.0 and  2.1  x  103.  Platelets and 
PMN  had  2.1  __+ 0.3  x  103 and  85  __+  15  ×  103  molecules per cell,  respectively. 
The unseparated mononuclear cells, purified monocytes, and lymphocytes from 
peripheral  blood had  35.7  +  4.4,  67.9  +  15,  and  32.8  +  9.7  ×  103  molecules 
per cell, respectively. Leu-1 + T  iymphocytes purified by FACS from the periph- 
eral blood of a  normal individual had 9.0 x  10  ~ molecules per cell.  Unseparated 
FtGUR~ 3.  Detection of DAF on different cell types by immunoprecipitation.  The NP-40 
extracts (1 ml each) of different cell types were incubated with anti-DAF IA  10-bearing protein 
A-Sepharose (20 t,I of beads) for 1 h in the cold. The bound DAF molecules were eluted by 
boiling the  beads  in  nonreducing  SDS  sample buffer, then subjected  to  SDS-PAGE and 
Western blotting as described above. DAF bands were detected by incubating the nitrocellulose 
125  7  paper with  I-labeled IA  10 (10  cpm) for 1 h at room temperature, followed by washing and 
autoradiography.  (Lanes  1 and  8)  Pure  DAF  from E  hu.  (2-7) Extracts  from cells: blood 
mononuclear cells (2), tonsil mononuclear cells (3), tonsil B lymphocytes (4), tonsil T lympho- 
cytes (5), PMN (6), and platelets (7). All cell types showed the DAF band. The size of DAF 
was different among different cells. KINOSHITA  ET  AL. 
TABLE  II 
Distribution of DaF Among Different Cell Types  from the Peripheral 
Blood of Normal Individuals and PNH Patients 
DAF Molecules (Xl0  -3) per cell 
Cells  _+ standard deviation 
Normal 
Erythrocytes  3.3 _.+_ 0.4 (35)* 
Platelets  2.1 ___ 0.3 (4) 
PMN  85.0 +  15.0 (4) 
Mononuclear, total  35.7 ___ 4.4 (3) 
Monocytes  67.9 _+ 15.0 (3) 
Lymphocytes  32.8 +  9.7 (3) 
PNH 
Erythrocytes 
Platelets 
1.1 (SB), 1.0 (GC), 0.9 (VR) 
0.6 (SB), not detectable (GC) 
* Number of samples examined. 
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FIGURE 4.  FAGS analysis of normal and PNH erythrocytes using antibodies to DAF. Eryth- 
rocytes from a normal individual and three PNH patients were stained with a mixture of three 
monoclonal anti-DAF and fluorescein isothiocyanate-goat F(ab')2 anti-mouse IgG (solid lines). 
Dashed lines represent control cells stained with a  mixture of monoclonal antibodies of the 
same subclasses but directed to nonrelevant antigens. (A) Normal; (B) PNH (patient SB); (C) 
PNH  (GC); (D) PNH  (VR). The  FAGS patterns of erythrocytes from several Other normal 
individuals were very similar to the one shown in this figure. 
mononuclear cells from a tonsil had 42 x  103 molecules per cell. Purified B and 
T  lymphocytes from this tonsil had  54 x  103 and  17 X  103 molecules per cell, 
respectively. 
The surface expression of DAF on different cell types from peripheral blood 
was  next  studied  by indirect  immunofluorescent  staining,  followed by FAGS 
analysis.  Erythrocytes  and  platelets  were  stained  with  a  mixture  of the  three 
monoclonal  antibodies  to  increase  the  fluorescence  intensity.  Buffy coat cells 
were stained only with IA10 anti-DAF. PMN, monocytes, and lymphocytes were 
separated according to their light scattering properties and analyzed separately. 
As shown in Figs. 4A, 5A, and 6A, all cell types expressed surface DAF. The 
fluorescence intensity  appeared normally  distributed  in all cells, except in  red 
cells, in  which the distribution  of DAF was very skewed in all individuals.  For 
example, the mean relative fluorescence intensity of the sample in Fig. 4A was 84  DECAY-ACCELERATING  FACTOR  IN  NORMAL  AND  PNH  BLOOD  CELLS 
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FIGURE  5.  FACS analysis of normal and PNH  platelets using antibodies to DAF.  Platelets 
from a  normal individual (A) and PNH patient SB (B) were stained with a  mixture of three 
monoclonal anti-DAF and fluorescein isothiocyanate-goat F(ab')2 anti-mouse IgG (solid lines). 
Dashed lines represent control staining with nonrelevant monoclonal antibodies. PNH patient 
SB had two populations of circulating platelets. 
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FIGURE 6.  FACS analysis of leukocytes from a  normal individual and three PNH patients 
using antibodies to DAF. Buffy coat cells from a normal individual (A) and three PNH patients, 
SB (B), GC (C), and VR (D) were stained with monoclonal antibody IA10 anti-DAF or with a 
nonrelevant antibody, followed by fluorescein isothiocyanate-goat F(ab')2 anti-mouse IgG. 
Results on monocytes,  PMN, and lymphocytes are shown separately. (Solid lines) anti-DAF; 
(dashed lines) control antibody. 
120, but a sizable proportion of the red cells showed intensities >300.  In three 
individuals, the red cells were separated on the basis of density into four fractions, 
by centrifugation in a Percoll gradient. We found that DAF expression decreased 
with red cell density, and that the lightest cells had  19.4 +  0.2% higher levels of 
DAF  than  the  densest  cells.  However,  the  skewed  DAF  distribution  was  still 
observed in all fractions (not shown). 
By  FACS  analysis,  monocytes  showed  the  highest  DAF  surface  expression 
(mean fluorescent intensity, 756). Although, among extracts of blood cells, PMN 
had  the highest  amount of DAF (Table II),  the surface expression of DAF in 
PMN (mean fluorescent intensity, 212) was much lower than that of monocytes. KINOSHITA  ET  AL.  85 
Lymphocytes appeared as two distinct populations. The major population, ~65% 
of total  lymphocytes, expressed less  surface DAF (mean fluorescent intensity,. 
109)  than  the  minor population  (mean fluorescent intensity,  349)  (Fig.  6A). 
When  the  buffy  coat  cells  were  simultaneously stained  with  phycoerythrin- 
conjugated anti-Leu-1 (a pan T reagent) and anti-DAF, >90% of the lymphocytes 
with high DAF expression were Leu-1- (not shown). This agrees with results of 
the IRMA,  which showed that an extract of tonsil  B  cells had levels of DAF 
about three times higher than an extract of T  cells, and with the finding that T 
iymphocytes purified by cell sorting had a very low DAF content (see above). 
Quantitation  of DAF in Erythrocytes from  Patients  With PNH.  DAF  levels in 
extracts  of erythrocytes from  three  PNH  patients  (SB,  GC,  and  VR)  were 
measured by two-site IRMA and found to be much lower than normal (1,100, 
1,000, and 900 molecules per ceil, respectively) (Table II). To obtain information 
about  the pattern  of surface expression of DAF,  erythrocytes from the same 
patients were studied by FACS. In patients who required no blood transfusions 
in the previous 6 mo (SB and VR, Fig. 4, B and D), two populations of red cells 
were detected.  One was  DAF deficient and constituted ~60%  of the total  in 
patient SB, ~30% in patient VR. The second population of red cells was positive 
and contained normal levels of DAF in patient SB but low levels in patient VR. 
Analysis of the red cells of the third patient (GC) was complicated by the fact 
that  she had  frequent hemolytic crises and  received transfusions.  The  FACS 
pattern again revealed two populations of cells, one DAF negative (40%) and the 
other bearing lower than normal DAF levels (Fig. 4 C). To examine the possibility 
that the DAF-containing cells originated at least in part from the blood transfu- 
sions,  we separated the two populations  by affinity chromatography and acid 
lysis (see Materials and Methods) and determined their reticulocyte contents. We 
expected the proportion of immature cells to be much higher among the patient's 
own erythrocytes than in the transfused cells. Indeed, we found that, while the 
unfractionated red  cells  contained  10%  reticulocytes, the  DAF-negative  and 
-positive cells contained 17 and 2% reticulocytes, respectively. In contrast, when 
the red cells from  the nontransfused patients  were fractionated by  the same 
method, the reticulocyte contents of the unseparated cells and the DAF-positive 
cells were not significantly different (2.1 vs.  1.6% in patient SB, and 0.9 vs. 0.6% 
in patient VR).  It appears, therefore, that most or all of patient GC's own red 
cells  were  DAF  negative.  Further  evidence  to  support  this  hypothesis  was 
obtained by blood typing DAF-negative and -positive populations from patient 
GC,  by  Dr.  Pablo  Rubinstein  (New  York  Blood  Center).  The  DAF-negative 
population was devoid of antigens E, N, Kell, and Kp  a, while the same antigens 
were present in the population of DAF-positive cells. 
When SB, GC, and VR erythrocytes were subjected to the Ham test, 54,  39, 
and  30%,  respectively,  were  lysed  by  complement.  To  find  out  which  cell 
population was complement sensitive, the patients' erythrocytes were first sub- 
jected  to  acidified serum  lysis  and  the  remaining cells  then  tested  for  DAF 
expression by FACS analysis. As shown in Fig. 7, the acidified serum preferen- 
tially lysed the DAF-negative cells. 86  DECAY-ACCELERATING  FACTOR  IN  NORMAL  AND  PNH  BLOOD  CELLS 
E 
(D 
PNH  (SB) 
f\ 
1  1~  ~  ~5~ 
PNH  (GC) 
ii  ,,o.e.  ® 
i  :30%  Serum  (~ 
ii  ,0%Serum ® 
1  100  200  300  400  500 
Relative  Fluorescence Intensity 
FIGURE 7.  Acidified serum lysis of PNH E  hu. Erythrocytes from the patients SB (A-C) and 
GC (D-F) (107 cells) were incubated with 100 #1 of buffer (A, D), 30% acidified serum (B, E), 
or 60% acidified serum (C, F) for 30 min at 37°C.  Unlysed cells were collected by centrifu- 
gation, washed three times with PBS, stained with monoclona[ antibodies to DAF or control 
antibodies as described in legend to Fig. 4, and then analyzed by FACS. (Solid lines) anti-DAF; 
(dashed  lines)  control  antibodies.  The  DAF-deficient  population  was  selectively  lysed  by 
acidified serum. 
In  short,  the  red  cells  from  these  patients  differed with  regard  to  DAF 
expression. In two of them (SB and VR), only some of the red cells were DAF 
negative and, in the third (GC), with the most severe hemolytic episodes, most 
or all endogenous cells were DAF negative.  In every instance only the DAF- 
negative population was lysed by complement in the Ham test. 
DAF Deficiency in Platelets and Leukocytes  from PNH Patients.  We next studied 
by FACS analysis the DAF surface expression in platelets and leukocytes from 
the same patients (Figs.  5B,  6, B-D). In patient SB (who had circulating DAF- 
negative and -positive red cells), neutrophils, monocytes, and platelets showed 
two distinct populations, one with normal amounts of DAF (23, 20, and 22% of 
each  of these  cell  types)  and  the  other  DAF  negative.  DAF  expression  on 
lymphocytes appeared normal (Figs.  5B, 6B). The patients GC and VR differed 
from the first in  two significant respects,  that  is,  single populations  of DAF- 
deficient neutrophils and monocytes were detected in  their peripheral  blood, 
and the lymphocytes were also DAF defective (Fig. 6, C and D). Small amounts 
of DAF were detected in the monocytes and neutrophils of patient VR, and in 
the lymphocytes from both VR and GC. 
DAF levels in extracts of platelets from two PNH patients (SB and GC) were 
measured by IRMA (Table II). Consistent with the results of FACS analysis, the 
platelets from patient SB contained ~30% of the normal level of DAF. No DAF 
was detected in the platelets of patient GC. KINOSHITA ET  AL.  87 
Discussion 
The present study reports quantitative information on the distribution of DAF 
in  normal  individuals  and  in  PNH  patients.  The  DAF  measurements  were 
performed  by  IRMA  and  FACS  analysis  using  monoclonal  antibodies  whose 
specificity was confirmed both by immunoblotting and by their inhibitory activity 
on DAF function.  These measurements  revealed that  DAF is present not only 
on red cells but on platelets, PMN, monocytes, and B and T  lymphocytes. 
The highest number of DAF molecules were found in neutrophils (8.5 ×  10  4 
per cell), followed by monocytes (6.8 ×  104), and lymphocytes (3.3 ×  10  4) (Table 
II).  In agreement with the recent findings of Rosen et al. (27), a  small number 
of DAF molecules were found in platelets (2.1  ×  103 per cell). Although both B 
and T  lymphocytes bear DAF, the results of FACS analysis and IRMA of tonsil 
iymphocytes showed that B lymphocytes had considerably more DAF molecules 
than  T  lymphocytes.  Interestingly,  the  highest  amounts  of DAF  were  found 
among phagocytes and B lymphocytes, cells believed to interact frequently with 
immune complexes and complement. 
The  results of the  IRMA and  FACS analysis were in  good agreement,  with 
one exception: by FACS analysis neutrophils had three times less DAF than did 
monocytes (Fig.  6A), contrary to the results obtained by IRMA of cell extracts 
(Table II). Perhaps, as in the case of CR1 and CR3, this discrepancy reflects the 
presence of an internal pool of DAF in neutrophils (28-30). 
We also found that  the Mr of DAF varies  among  different cell  types.  DAF 
from platelets and PMN was slightly larger (~5,000 Mr) than erythrocyte DAF, 
while  DAF  from  mononuclear  cells  was  of an  intermediate  size.  Small  size 
differences have been also detected among CR 1 molecules from different cells, 
but  the  significance  of these  structural  variations  in  DAF  and  CR1  remains 
obscure (31, 32). 
With  regard  to  red  cells,  the  distribution  of DAF  showed  one  intriguing 
feature.  Although  the  total  amount  of DAF on  red  cells from  normal  adults 
varied only about twofold (between 2.1 and 4.0 ×  103 molecules per cell; mean, 
3.3 ×  10s),  FACS analysis showed that in every individual its distribution varied 
as much as tenfold (Fig.  4A). This anomalous distribution could reflect hetero- 
geneity in DAF biosynthesis or catabolism in the bone marrow precursor popu- 
lation, and/or secondary changes associated with red cell aging. 
To  study  this  question,  we  fractionated  red  cells  from  several  individuals 
according to their density, and studied the DAF distribution  by FACS analysis. 
Although  the  fluorescence  intensity  continued  to  be  abnormally  distributed 
among cells from all  fractions,  the mean  amounts of DAF were smaller  in the 
denser  erythrocytes,  which  contain  the  older  population  of cells.  It  appears, 
therefore, that the aging of red cells in circulation is associated with DAF losses. 
This may be of interest because the removal of senescent red cells from circula- 
tion  is  enhanced  by  binding  autoantibodies  to  a  cryptic  epitope  of band  3 
glycoprotein  (33-35)  or to clusters  of this  glycoprotein  (36).  It is  conceivable 
that  the  decrease  in  DAF  facilitates  the  deposition  of C3b  and  subsequent 
interaction of the old erythrocytes, with scavenging cells of the reticuloendothe- 
lial  system.  In  support  of this  idea,  a  prior  study (37)  showed  that,  although 
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and complement, lysis gradually increased in older cells, reaching a maximum of 
~75% after 3-4 mo in circulation. 
With  regard  to  the  three  individuals  with  PNH,  the  most  important  new 
findings are that all circulating cells showed defects in surface expression of DAF 
antigen, that the DAF-negative and -positive cells could be present simultaneously 
in  the  circulation,  and  that  the  patterns  of DAF  deficiency were different in 
every patient (Table III). 
In  patient  SB,  two  populations  of  red  cells,  monocytes,  neutrophils,  and 
platelets  were found in  the peripheral  blood.  One  population was  profoundly 
deficient in  surface  DAF  while  the  other appeared  normal.  The  lymphocytes 
from this patient had a normal level of surface DAF. 
In the other two patients (GC, VR), the expression of DAF on the lymphocyte 
surface was also affected. In the patient with more severe disease  (GC),  PMN, 
monocytes,  and  most  red  cells  and  lymphocytes  were  DAF  negative.  Small 
amounts of DAF were detected in the blood elements of patient VR, suggesting 
that in this case the defect was caused by abnormal regulation of a  gene rather 
than by a nonfunctional or deleted gene. 
These observations offer additional  support for the  concept that  PNH  cells 
are of monoclonal origin and arise from the clonal expansion of an  abnormal 
bone marrow progenitor (38-40).  In patient SB, the erythroid, myeloid, as well 
as megakariocytic lineages were affected, suggesting that the mutation occurred 
in a common precursor. It is remarkable that in this patient, normal and abnormal 
elements from the three lineages were found in circulation,  ~¾  of them  DAF 
deficient.  This proportion remained  unchanged  in blood samples collected  10 
wk apart, reflecting perhaps a steady state between the proliferation of abnormal 
and  normal  bone  marrow precursors and  the  removal from circulation of the 
end  cells.  Because  in  patients  GC  and  VR  the  lymphocytes  were  also  DAF 
deficient, a  more primitive cell giving rise to all  blood elements was  probably 
TABLE  III 
Distribution of DAF in Cells  from Peripheral Blood of PNH Patients 
Cell type 
Expression of DAF in PNH patients 
Patient SB  Patient GC  Patient VR 
Erythrocytes  60% Undetectable  40% Undetectable 
40% Normal  60% Below normal* 
30% undetectable 
70% low levels 
Platelets  78% Undetectable 
22% Normal 
Undetectable (by IRMA)  ND* 
Monocytes  80% Undetectable  Undetectable 
20% Normal 
Very low 
PMN  77% Undetectable  Undetectable 
23% Normal 
Very low 
Lymphocytes  Normal  Very low or undetectable  Very low 
* Most or all cells in this population represent transfused donor cells. 
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affected. Such totipotent stem cells have not been isolated or morphologically 
identified, but there is compelling evidence for their presence in the postnatal 
bone marrow of mammals (41, 42). 
Although the sequence of events leading to the multiple abnormalities found 
in the membranes of PNH cells remains to be explained, our studies are relevant 
to  the pathogenesis of the disease.  The  DAF  defect can explain  some of its 
characteristic features, such as the large accumulation of C3 fragments on the 
surface of erythrocytes, PMN, and platelets and their abnormal susceptibility to 
lysis by complement (7,  10-12). Indeed, we have shown elsewhere (5) that DAF 
inhibits  the assembly of C3  convertases and prevents  C3b  deposition  on  cell 
surfaces, and we present direct evidence (Fig.  7) that  DAF-deficient cells are 
preferentially lysed when subjected to acidified fresh serum (Ham test). However, 
the relationship between the C3b accumulation on leukocytes and platelets and 
the observed thrombocytopenia, leukopenia, and enhanced propensity for throm- 
bosis and infection (43) is not clear. Others have suggested that C3b deposition 
on platelets leads to their aggregation, release reaction, and enhanced clotting 
(11), and that C3b deposition on the PNH neutrophils results in a  chemotactic 
defect (44). 
However, on the basis of current knowledge of DAF function, it is difficult to 
explain  the heightened susceptibility of cells from some PNH  patients to  the 
isolated  C5b-9  attack  complex  (45).  Further  studies  are  required  to  verify 
whether this is secondary to the DAF defect or whether an unrelated abnormality 
of the cell membrane is involved. 
Summary 
Decay-accelerating factor (DAF) is a  70,000 Mr protein that has been isolated 
from the membrane of red cells. The function of DAF is to inhibit the assembly 
of amplifying enzymes of the complement cascade on the cell surface, thereby 
protecting them from damage by autologous complement. We raised monoclonal 
antibodies to  DAF  and  used them  to  study its  distribution  in  cells from the 
peripheral blood of normal individuals and of patients with paroxysmal nocturnal 
hemoglobinuria (PNH), a disease characterized by the unusual susceptibility of 
red cells to the hemolytic activity of complement. 
The results of immunoradiometric assays and of fluorescence-activated cell 
sorter analysis showed that DAF was present not only on red cells but was widely 
distributed on the surface membrane of platelets, neutrophils, monocytes, and B 
and  T  lymphocytes. By  Western  blotting,  we  observed  small  but  consistent 
differences in the Mr of DAF from the membranes of various cell types. Quan- 
titative studies showed that phagocytes and B  lymphocytes, which presumably 
enter more frequently in contact with immune complexes and other potential 
activators of complement, had the highest DAF levels. 
As previously reported by others, the red cells from PNH patients were DAF 
deficient. When the patients' red cells were incubated in acidified serum (Ham 
test), only the DAF-deficient cells were lysed. In addition, we detected defects in 
DAF expression on platelets and all types of leukocytes. The observed patterns 
of DAF deficiency in these patients were consistent with the concept that the 
PNH cells were of monoclonal origin. In one patient, abnormal and normal cells 90  DECAY-ACCELERATING FACTOR  IN  NORMAL  AND  PNH  BLOOD  CELLS 
were found only in the erythroid, myeloid, and megakariocytic lineages. In two 
other  patients,  the  lymphocytes  were  also  DAF  deficient,  suggesting  that  a 
mutation occurred in a totipotent stem cell. It appears, therefore, that the lesion 
leading to PNH can occur at various stages in the differentiation of hematopoietic 
cells. 
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